###begin article-title 0
Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes regulatory T cell activity
###end article-title 0
###begin p 1
###xml 147 172 147 172 <email xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">glinkay@smh.toronto.on.ca</email>
Correspondence: Department of Laboratory Medicine, St. Michael's Hospital, 30 Bond Street, Room 2-013CC, Toronto, Ontario, Canada M5B 1W8. E-mail: glinkay@smh.toronto.on.ca
###end p 1
###begin p 2
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
###xml 628 631 610 613 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">165</sub>
###xml 970 971 946 947 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 990 991 966 967 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1065 1066 1038 1039 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 1176 1177 1146 1147 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1181 1182 1151 1152 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 1186 1187 1156 1157 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
Neuropilin-1 (Nrp1) is a multifunctional protein, identified principally as a receptor for the class 3 semaphorins and members of the vascular endothelial growth factor (VEGF) family, but it is capable of other interactions. It is a marker of regulatory T cells (Tr), which often carry Nrp1 and latency-associated peptide (LAP)-TGF-beta1 (the latent form). The signaling TGF-beta1 receptors bind only active TGF-beta1, and we hypothesized that Nrp1 binds the latent form. Indeed, we found that Nrp1 is a high-affinity receptor for latent and active TGF-beta1. Free LAP, LAP-TGF-beta1, and active TGF-beta1 all competed with VEGF165 for binding to Nrp1. LAP has a basic, arginine-rich C-terminal motif similar to VEGF and peptides that bind to the b1 domain of Nrp1. A C-terminal LAP peptide (QSSRHRR) bound to Nrp1 and inhibited the binding of VEGF and LAP-TGF-beta1. We also analyzed the effects of Nrp1/LAP-TGF-beta1 coexpression on T cell function. Compared with Nrp1- cells, sorted Nrp1+ T cells had a much greater capacity to capture LAP-TGF-beta1. Sorted Nrp1- T cells captured soluble Nrp1-Fc, and this increased their ability to capture LAP-TGF-beta1. Conventional CD4+CD25-Nrp1- T cells coated with Nrp1-Fc/LAP-TGF-beta1 acquired strong Tr activity. Moreover, LAP-TGF-beta was activated by Nrp1-Fc and also by a peptide of the b2 domain of Nrp1 (RKFK; similar to a thrombospondin-1 peptide). Breast cancer cells, which express Nrp1, also captured and activated LAP-TGF-beta1 in a Nrp1-dependent manner. Thus, Nrp1 is a receptor for TGF-beta1, activates its latent form, and is relevant to Tr activity and tumor biology.
###end p 3
###begin title 4
INTRODUCTION
###end title 4
###begin p 5
###xml 279 282 279 282 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">165</sub>
###xml 325 326 325 326 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">1</xref>
###xml 328 329 328 329 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">2</xref>
###xml 599 600 599 600 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B3" ref-type="bibr">3</xref>
###xml 837 838 836 837 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B4" ref-type="bibr">4</xref>
###xml 1021 1022 1017 1018 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">1</xref>
###xml 1024 1025 1020 1021 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">2</xref>
###xml 1027 1028 1023 1024 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B4" ref-type="bibr">4</xref>
###xml 1028 1029 1024 1025 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B5" ref-type="bibr">5</xref>
###xml 1029 1030 1025 1026 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B6" ref-type="bibr">6</xref>
###xml 1030 1031 1026 1027 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B7" ref-type="bibr">7</xref>
###xml 1031 1032 1027 1028 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B8" ref-type="bibr">8</xref>
###xml 1032 1033 1028 1029 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B9" ref-type="bibr">9</xref>
###xml 1033 1035 1029 1031 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B10" ref-type="bibr">10</xref>
###xml 1195 1196 1191 1192 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">1</xref>
###xml 1198 1199 1194 1195 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">2</xref>
###xml 1201 1202 1197 1198 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B7" ref-type="bibr">7</xref>
###xml 1204 1205 1200 1201 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B8" ref-type="bibr">8</xref>
Neuropilin-1 (Nrp1) is a multifunctional protein involved in axonal guidance through its ability to bind the chemorepulsive class 3 semaphorin (SEMA3) proteins and angiogenesis through its interactions with vascular endothelial growth factor (VEGF) family members (including VEGF165) and their receptors (VEGFR1 and VEGFR2) [1, 2]. It is a 130- to 140-kD type-1 membrane glycoprotein with a short cytoplasmic domain that has no apparent signaling motif but interacts with the post-synaptic density 95/Discs large/zona occludens (PDZ) protein denoted Nrp1-interacting protein, C (also denoted GIPC) [3]. The extracellular component consists of a1/a2, b1/b2, and c (meprin, A5 protein, protein tyrosine phosphatase mu) domains. The a1/a2 domains are involved in SEMA3 binding, and the b1/b2 domains are involved in SEMA3 and VEGF binding [4]. Nrp1 has affinity for other molecules including heparin, the peptide Tuftsin (TKPR), integrin beta1, cMet, hepatocyte growth factor (HGF), and some heparin-binding growth factors [1, 2, 45678910]. Of note, Nrp1 or the homologous Nrp2 (45% homology with Nrp1) is frequently expressed by malignant tumor cells and contributes to their malignant potential [1, 2, 7, 8].
###end p 5
###begin p 6
###xml 66 68 66 68 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B11" ref-type="bibr">11</xref>
###xml 105 107 105 107 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B12" ref-type="bibr">12</xref>
###xml 441 443 438 440 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B13" ref-type="bibr">13</xref>
###xml 661 663 649 651 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B14" ref-type="bibr">14</xref>
###xml 747 749 735 737 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B15" ref-type="bibr">15</xref>
###xml 1188 1189 1161 1162 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1210 1211 1183 1184 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 1263 1264 1236 1237 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1268 1269 1241 1242 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 1273 1274 1246 1247 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 1505 1506 1472 1473 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
In the immune system, Nrp1 is expressed by dendritic cells (DCs) [11] and regulatory T cells (Tr cells) [12]. In DCs, it is found at the immunologic synapse, but no definitive function has yet been attached to its expression by Tr cells. Interestingly, Tr cells frequently bear latency-associated peptide (LAP)-TGF-beta1, i.e., the latent form of this cytokine, and this appears to contribute to their suppressive activity in some settings [13]. The classical TGF-beta1 receptors (TGF-betaRI, -RII, and -RIII) bind only the active (mature) form of TGF-beta1, and other receptors must be involved. Indeed, arginine-glycine-aspartic acid (RGD)-binding integrins [14] and the mannose-6-phosphate/insulin-like growth factor II receptor (M6P/IGFII-R) [15] can bind LAP-TGF-beta1. However, these receptors appear be more relevant to DCs or macrophages and to our knowledge, have not been reported on Tr cells. We hypothesized that Nrp1 might be a receptor for LAP-TGF-beta1, and indeed, we found that Nrp1-Fc (but not Fc) bound LAP-TGF-beta1 and active TGF-beta1 at high affinity. Interestingly, LAP-TGF-beta competed with VEGF for binding to Nrp1-Fc and appeared to bind at the same site. Nrp1+ T cells, unlike Nrp1- T cells, captured LAP efficiently. Conventional CD4+CD25-Nrp1- T cells could be coated with Nrp1-Fc, which promoted the capture of LAP-TGF-beta1 and imparted regulatory activity to these cells. Importantly, we found that Nrp1 activates LAP-TGF-beta1, and this can occur on the membrane of Nrp1+ tumor cells. Thus, our study reveals that Nrp1 is a TGF-beta1 receptor, which is relevant to immune regulation and tumor biology.
###end p 6
###begin title 7
MATERIALS AND METHODS
###end title 7
###begin title 8
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 8
###begin p 9
###xml 64 68 <span type="species:ncbi:10090">mice</span>
Experiments were performed with the T cells of CD-1 and C57BL/6 mice (Charles River, Wilmington, MA, USA).
###end p 9
###begin title 10
Nrp1-Fc, Fc, and peptides
###end title 10
###begin p 11
###xml 12 15 <span type="species:ncbi:10116">rat</span>
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 161 166 <span type="species:ncbi:10090">mouse</span>
###xml 171 174 <span type="species:ncbi:10116">rat</span>
###xml 205 210 <span type="species:ncbi:10090">mouse</span>
###xml 215 220 <span type="species:ncbi:9606">human</span>
###xml 304 309 <span type="species:ncbi:9606">human</span>
Recombinant rat Nrp1, conjugated to an Fc fragment of human IgG1 (Nrp1-Fc), was purchased from R&D Systems (Minneapolis, MN, USA). There is 98% homology between mouse and rat Nrp1 and 93% homology between mouse and human Nrp1. A construct of identical sequence but containing only the spacer peptide and human IgG1-Fc fragment (R&D Systems) was used as a control (referred to as Fc). Peptides were synthesized by the Sheldon Biotechnology Centre (Montreal, Canada) and were >95% pure. The LAP C-terminal peptide was used in the N-acetylated QSSRHRR-OH form.
###end p 11
###begin title 12
###xml 26 29 23 26 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">165</sub>
TGF-beta1 components, VEGF165, and antibodies
###end title 12
###begin p 13
###xml 70 73 67 70 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">165</sub>
###xml 212 215 206 209 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">165</sub>
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 107 112 <span type="species:ncbi:10090">Mouse</span>
###xml 191 196 <span type="species:ncbi:10090">Mouse</span>
###xml 202 207 <span type="species:ncbi:9606">human</span>
###xml 220 225 <span type="species:ncbi:10090">mouse</span>
###xml 231 236 <span type="species:ncbi:9606">human</span>
###xml 286 292 <span type="species:ncbi:9986">rabbit</span>
###xml 298 301 <span type="species:ncbi:10116">rat</span>
###xml 410 415 <span type="species:ncbi:10090">mouse</span>
###xml 494 500 <span type="species:ncbi:9986">rabbit</span>
###xml 506 509 <span type="species:ncbi:10116">rat</span>
All recombinant TGF-beta component proteins and human recombinant VEGF165 were purchased from R&D Systems. Mouse anti-TGF-beta-antibody was purchased from BD Biosciences (San Jose, CA, USA). Mouse anti-human VEGF165 and mouse anti-human LAP antibodies were from R&D Systems. Polyclonal rabbit anti-rat Nrp1 developed against the Nrp814-827 peptide was purchased from Oncogen (Seattle, WA, USA). We also used a mouse anti-Nrp1 mAb (R&D Systems, clone 130603) binding to a different epitope than rabbit anti-rat Nrp1.
###end p 13
###begin title 14
Cell enrichment and culture
###end title 14
###begin p 15
###xml 50 52 50 52 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B16" ref-type="bibr">16</xref>
###xml 59 60 59 60 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 745 746 745 746 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 750 751 750 751 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 759 760 759 760 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 764 765 764 765 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 153 159 <span type="species:ncbi:9986">rabbit</span>
###xml 165 168 <span type="species:ncbi:10116">rat</span>
###xml 169 174 <span type="species:ncbi:10090">mouse</span>
###xml 216 220 <span type="species:ncbi:9925">goat</span>
###xml 226 232 <span type="species:ncbi:9986">rabbit</span>
Mouse splenic T cells were isolated as described [16]. Nrp1+ T lymphocytes were isolated by positive magnetic sorting. In brief, cells were treated with rabbit anti-rat/mouse Nrp1 antibody (Oncogen) and biotinylated goat anti-rabbit antibody (BD PharMingen, San Diego, CA, USA). The mixture was then incubated with magnetic particles attaching to the biotinylated antibodies [streptavidin ferrofluid (R&D Systems)], and the labeled cells were separated in a magnetic field. Sorted cells were greater than 95% Nrp1-positive. CD4+ spleen cells were isolated by negative sorting using the EasySep CD4 enrichment kit from StemCell Technology (Canada), according to the manufacturer's instructions. Further separation steps involved collection of CD4+CD25+ and CD4+CD25- using biotinylated anti-CD25 antibody and the same protocol as above.
###end p 15
###begin p 16
###xml 152 157 <span type="species:ncbi:10090">mouse</span>
T cells were cultured in AIM V serum-free medium (Invitrogen Canada, Ontario), supplemented with 50 muM 2-ME, 1 mM sodium pyruvate, and 2 mM HEPES. The mouse T cell line HT-2 (ATCC, Manassas, VA, USA) was grown in DMEM + 5% FBS medium containing 10 ng/ml IL-2 and 2-ME, and this was replaced by the same medium containing 5 ng/ml IL-4 instead of IL-2 for the TGF-beta assay.
###end p 16
###begin title 17
Binding to protein G-sepharose columns
###end title 17
###begin p 18
This was performed with Protein G-sepharose microcolumns (HiTrap Protein G HP by Amersham Pharmacia Biotech, Uppsala, Sweden). Retained proteins were eluted in glycine buffer, pH 3.5, and subjected to SDS electrophoresis under reducing conditions. Immunoblots were developed in specific antibodies and avidin-HRP.
###end p 18
###begin title 19
ELISA-binding assays
###end title 19
###begin p 20
###xml 658 664 <span type="species:ncbi:9986">rabbit</span>
###xml 670 675 <span type="species:ncbi:10090">mouse</span>
Nrp1-Fc or other proteins were directly immobilized to Nunc Maxisorb plates (Nalge Nunc International, Rochester, NY, USA), according the manufacturer's instructions. Soluble ligands were incubated in the precoated plate for 2 h at room temperature or at 4degreesC overnight. Nonspecific binding was determined in wells treated with the blocking solution and specific antibody and subtracted from the OD for total binding to give the values of specific binding. The binding plate was treated with anti-TGF-beta1, anti-LAP, or control antibodies, diluted to a final concentration 500 ng/ml in 0.1% BSA + 0.05% Tween 20, followed by the secondary biotinylated rabbit anti-mouse antibodies and HRP reaction. The assays were performed in duplicates. In some cases, we also determined the concentration of unbound (soluble) components by ELISA. Calculations and regression analysis were performed in GraphPad Prism software (GraphPad Software, Inc., San Diego, CA, USA). When necessary, the fits for alternative equations were compared.
###end p 20
###begin title 21
Tr cell assays
###end title 21
###begin p 22
###xml 18 19 18 19 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 23 24 23 24 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 74 75 74 75 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 453 454 444 445 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 458 459 449 450 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 622 624 613 615 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B17" ref-type="bibr">17</xref>
###xml 699 700 690 691 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 704 705 695 696 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 709 710 700 701 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 740 741 731 732 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 1075 1077 1062 1064 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B18" ref-type="bibr">18</xref>
Splenic sorted CD4+CD25- T cells were incubated with Nrp1-Fc (or not; 8x106 cells; final concentration, Nrp1-Fc was 5 nM in AIM V serum-free medium) at 37degreesC for 40 min. Unbound ligands were washed off. As a second step, Nrp1-Fc-pulsed cells (or control cells) were treated with LAP-TGF-beta1 (or not) as above and washed. As a control, Nrp1-Fc was replaced by Fc. Tr (suppressor, Ts) cell assays were performed by adding these treated cells to CD4+CD25- T cells (effector/responder cells, Te) and measuring the decline in soluble CD3-stimulated proliferation (and IL-2 secretion), as described by Piccirillo et al. [17], except that assays were performed in serum-free medium. In brief, 5 x 105 CD4+CD25- cells were plated over 2 x 105 irradiated, T cell-depleted spleen cells, and increasing numbers of Tr cells were added. Soluble anti-CD3 antibody was added at 2 mug/ml. In some wells, a mAb (1D11) that neutralizes active TGF-beta was added to determine whether suppression was mediated by this cytokine. Proliferation was determined with a MTT assay as described [18]. The percent suppression of responses was calculated as follows: Percent suppression = [1-(OD of Te+Ts)/(OD of Te)] x 100.
###end p 22
###begin title 23
Flow cytometry
###end title 23
###begin p 24
###xml 63 65 63 65 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B16" ref-type="bibr">16</xref>
These analyses were performed as we have described previously [16] on a FACSCalibur flow cytometer.
###end p 24
###begin title 25
Phospho-(p)-Smad2 staining
###end title 25
###begin p 26
###xml 97 102 <span type="species:ncbi:9606">human</span>
###xml 104 109 <span type="species:ncbi:10090">mouse</span>
###xml 119 125 <span type="species:ncbi:9986">rabbit</span>
###xml 229 233 <span type="species:ncbi:9925">goat</span>
###xml 239 245 <span type="species:ncbi:9986">rabbit</span>
The cells were fixed in 4% formaldehyde and permeabilized in Triton X-100 before staining. Anti (human, mouse)-p-Smad2 rabbit IgG (Chemicon International, El Segundo, CA, USA) was used in a 1:500 dilution. Secondary antibody was goat anti-rabbit, FITC-conjugated IgG (Sigma Chemical Co., St. Louis, MO, USA), diluted 1:100.
###end p 26
###begin title 27
Statistical analysis
###end title 27
###begin p 28
###xml 219 220 219 220 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 236 237 236 237 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Statistical analyses were performed with the GraphPad Prism 3.0 program (GraphPad Software Inc.). In each experiment, the significance of differences between experimental and control results was determined by Student's t-test or ANOVA. P < 0.05 was considered significant.
###end p 28
###begin title 29
RESULTS
###end title 29
###begin title 30
TGF-beta1, free LAP, and LAP-TGF-beta1 bind to Nrp1
###end title 30
###begin p 31
###xml 302 309 293 300 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 1A</bold>
###xml 302 309 293 300 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig"><bold>Fig. 1A</bold></xref>
Protein G captured Nrp1-Fc or control Fc but not other components as a result of its Fc-binding capacity (not shown). We found that free beta1-LAP, LAP-TGF-beta1, and active TGF-beta1 (like VEGF) all bound to the Nrp1-Fc-coated beads but not to control Fc-coated beads as determined by immunoblotting (Fig. 1A). Nrp1-Fc failed to bind IFN-gamma or IL-2 (not shown).
###end p 31
###begin p 32
###xml 135 152 129 146 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">(Fig. 1, B and C)</xref>
###xml 998 1007 976 985 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">(Fig. 1D)</xref>
Binding was also observed in ELISA cell-free assays. Plates coated with Nrp1-Fc retained active TGF-beta1, free LAP, and LAP-TGF-beta1 (Fig. 1, B and C). Heparin was not required for binding and prevented the binding of LAP but not TGF-beta1. The cytokines IL-2 and IFN-gamma did not bind to Nrp1-Fc (not shown). Active or latent TGF-beta1 did not bind to immobilized Fc, and soluble Fc did not compete with soluble TGF-beta1 for binding to immobilized Nrp1-Fc. No binding of any TGF-beta1 components was noted when Nrp1-Fc was replaced by OVA, aprotinin, leupeptin, and a number of unrelated peptides (data not shown). To confirm specificity, we also performed blocking experiments with antibodies. Soluble LAP, when mixed with soluble Nrp1-Fc, competed with plate-bound LAP and decreased Nrp1-Fc retention on the plate (data not shown). Pretreatment of immobilized LAP with neutralizing concentrations of anti-LAP antibodies but not control antibody blocked the binding of soluble Nrp1-Fc to LAP (Fig. 1D).
###end p 32
###begin p 33
###xml 208 210 208 210 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 243 244 243 244 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 244 245 244 245 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 343 345 343 345 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 346 347 346 347 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 347 348 347 348 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 418 420 415 417 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 475 478 466 469 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">sem</sc>
###xml 557 558 545 546 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 558 559 546 547 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 582 585 566 569 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">sem</sc>
###xml 662 663 646 647 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 689 690 670 671 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 833 842 811 820 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">(Fig. 1B)</xref>
Binding affinities were determined under equilibrium conditions by ELISA. This approach is sensitive and avoids the complexity of determining the kinetics of bivalent interactions. Affinity is expressed as EC50, an integrative equivalent of a Kd used when cooperativity between binding sites is observed (when binding sites do not interact, EC50=Kd). The affinity of LAP and LAP-TGF-beta1 for Nrp1 was notably high: EC50 = 359 +/- 80 and 338 +/- 116 pM, respectively (mean+/-sem of seven or more experiments). Affinity for active TGF-beta1 was even higher: Kd = 40 +/- 8 pM (mean+/-sem of seven experiments). Strong positive cooperativity was observed for LAP (nH=2.9) and LAP-TGF-beta1 (nH=3.7) binding to Nrp1-Fc (but not for TGF-beta1 binding), suggesting that LAP binds to three or more interacting sites on the Nrp1-Fc molecule (Fig. 1B). To exclude possible effects of immobilization, we also measured reactant concentrations in soluble mixtures after filtration through Millipore filters with the molecular cut-off permitting separation of the unbound from the bound components. We also examined other variations of the assay (ELISA of the unbound instead of the retained ligands; immobilization of the ligand instead of the receptor protein). These alternative assays generated similar binding-affinity results (data not shown) to those reported above.
###end p 33
###begin title 34
###xml 46 49 43 46 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">165</sub>
TGF-beta1 and LAP components compete with VEGF165 for binding to Nrp1
###end title 34
###begin p 35
###xml 79 82 73 76 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">165</sub>
###xml 107 116 101 110 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 2, A</bold>
###xml 121 122 115 116 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 107 122 101 116 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig"><bold>Fig. 2, A</bold> and <bold>B</bold></xref>
###xml 193 195 184 186 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 259 268 246 255 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig">(Fig. 2B)</xref>
###xml 277 286 264 273 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig">(Fig. 2A)</xref>
Remarkably, LAP, LAP-TGF-beta1, and active TGF-beta1 diminished binding of VEGF165 to immobilized Nrp1-Fc (Fig. 2, A and B). LAP was a more effective competitor than active TGF-beta1 with an IC50 = 0.28 nM versus 0.89 nM, respectively. In contrast, IFN-gamma (Fig. 2B) and BSA (Fig. 2A) did not compete.
###end p 35
###begin p 36
###xml 71 72 71 72 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B5" ref-type="bibr">5</xref>
###xml 74 75 74 75 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B6" ref-type="bibr">6</xref>
###xml 98 115 98 115 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig">(Fig. 2, C and D)</xref>
###xml 266 268 266 268 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 395 398 393 396 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">165</sub>
###xml 446 455 441 450 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig">(Fig. 2D)</xref>
Some ligands bind to Nrp1 through an arginine-rich C-terminal segment [5, 6]. In accord with this (Fig. 2, C and D), the C-terminal LAP-derived peptide QSSRHRR (but not an unrelated peptide) bound Nrp1-Fc, although with an affinity tenfold lower than that of LAP (EC50=4.18+/-0.99 nM), perhaps because of its monomeric form. In the soluble form, the QSSRHRR peptide inhibited the binding of VEGF165, LAP, and LAP-TGF-beta1 to plate-bound Nrp1-Fc (Fig. 2D). Although VEGF binding could be blocked completely, the binding of LAP and LAP-TGF-beta1 was markedly reduced but not completely inhibited. A modified peptide where the arginine was replaced by glutamic acid did not prevent binding (data not shown).
###end p 36
###begin title 37
Coexpression of Nrp1 and LAP-TGF-beta1 in T cell populations
###end title 37
###begin p 38
###xml 45 52 45 52 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 3A</bold>
###xml 45 52 45 52 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig"><bold>Fig. 3A</bold></xref>
###xml 79 81 79 81 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B19" ref-type="bibr">19</xref>
###xml 107 108 107 108 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 116 117 116 117 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 235 244 235 244 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">(Fig. 3B)</xref>
###xml 386 388 386 388 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B11" ref-type="bibr">11</xref>
###xml 578 579 578 579 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 582 583 582 583 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 605 614 605 614 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">(Fig. 1B)</xref>
Only 3-4% of splenic T cells expressed Nrp1 (Fig. 3A), as previously reported [19], and almost all were CD4+ and CD8- (data not shown). Some Nrp1-negative T cells incubated with soluble Nrp1-Fc captured this molecule on their membrane (Fig. 3B), and we made use of this finding in some of our subsequent experiments. The ability of T cells to capture Nrp1 has been reported previously [11], but the mechanism is unclear. It is not a result of FcRs, as FcR-blocking antibodies had no effect. Importantly, Nrp1-Fc incubation followed by LAP incubation increased the number of Nrp1+LAP+ T cells considerably (Fig. 1B).
###end p 38
###begin p 39
###xml 212 213 212 213 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 233 244 233 244 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">Fig. 3, C&#8211;E</xref>
###xml 287 288 287 288 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 292 293 292 293 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 327 336 327 336 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">(Fig. 3C)</xref>
###xml 380 381 380 381 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 385 386 385 386 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 390 391 390 391 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 527 528 527 528 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 532 533 532 533 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 569 578 569 578 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">(Fig. 3D)</xref>
###xml 619 620 607 608 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 735 736 723 724 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 740 741 728 729 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 745 746 733 734 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 786 787 774 775 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 791 792 779 780 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 796 797 784 785 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
We used four-color flow cytometry to analyze the coexpression of CD4, CD25, Nrp1, FoxP3, and LAP in splenic T cells. The expression of these markers did not completely overlap, indicating heterogenity in the Nrp1+ T cell population (Fig. 3, C-E; data not shown). Approximately 60% of CD4+CD25+ T cells coexpressed Nrp1 and LAP (Fig. 3C). There was a smaller number (10-12%) of CD4+CD25+Nrp1- T cells that also expressed LAP, suggesting that Nrp1 is not the only LAP receptor expressed by these T cells. Approximately 45% of CD4+CD25+ T cells coexpressed Nrp1 and FoxP3 (Fig. 3D). Interestingly, approximately35% of Nrp1- T cells also expressed FoxP3, but most of these cells stained at a lower intensity for FoxP3. We conclude that CD4+CD25+Nrp1+ express FoxP3 at higher levels than CD4+CD25+Nrp1- T cells.
###end p 39
###begin p 40
###xml 17 18 17 18 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 27 28 27 28 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</bold>
###xml 27 28 27 28 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><bold>&#8211;</bold></sup>
###xml 168 169 168 169 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 173 174 173 174 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 278 287 278 287 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">(Fig. 3E)</xref>
###xml 374 375 374 375 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 379 380 379 380 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 404 421 404 421 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">Figure 3, C and D</xref>
###xml 457 458 457 458 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 462 463 462 463 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 494 503 494 503 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">(Fig. 3E)</xref>
###xml 549 550 549 550 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 554 555 554 555 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 658 659 658 659 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 663 664 663 664 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 759 760 747 748 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 803 812 791 800 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">(Fig. 3F)</xref>
###xml 842 843 830 831 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</bold>
###xml 842 843 830 831 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><bold>&#8211;</bold></sup>
###xml 865 874 853 862 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">(Fig. 3F)</xref>
###xml 977 984 965 972 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">Fig. 3G</xref>
###xml 1016 1023 1004 1011 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">Fig. 3B</xref>
###xml 1131 1140 1116 1125 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">(Fig. 3G)</xref>
###xml 1511 1512 1487 1488 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1519 1528 1495 1504 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">(Fig. 3H)</xref>
###xml 71 77 <span type="species:ncbi:9986">rabbit</span>
We separated Nrp1+ and Nrp1- splenic T cells by magnetic sorting using rabbit polyclonal anti-Nrp1 antibody. In accord with the findings mentioned above, the sorted CD4+Nrp1+ splenic T cell population was enriched for cells expressing Tr markers, including LAP, FoxP3, and CD25 (Fig. 3E). It should be noted that this population overlaps with but is not identical to the CD4+CD25+ population analyzed in Figure 3, C and D, as approximately two-thirds of CD4+Nrp1+ T cells does not express CD25 (Fig. 3E). Thus, LAP was expressed by 40% of sorted CD4+Nrp1+ T cells, and FoxP3 and CD25 were expressed at a slightly lower frequency. When we incubated sorted CD4+Nrp1+ cells with free LAP, we observed that they captured LAP, such that approximately95% became LAP+, and this was blocked by an anti-Nrp1 mAb (Fig. 3F). In contrast, few sorted Nrp1- T cells captured LAP (Fig. 3F). Indeed, we found that the latter cells captured LAP poorly, unless they were precoated with Nrp1-Fc (Fig. 3G; in accord with the results of Fig. 3B with unsorted T cells), and LAP-TGF-beta1 binding to Nrp1-Fc-coated T cells was inhibited by anti-Nrp1 mAb (Fig. 3G). These flow cytometry results, especially the blockade of binding by anti-Nrp1 antibodies, support the conclusion that Nrp1 is a LAP-TGF-beta1 receptor. Unsorted T cells incubated with active TGF-beta1 captured this cytokine (they have receptors for the active form), but even in this case, preincubation of cells with Nrp1-Fc moderately increased the number of TGF-beta+ cells (Fig. 3H), consistent with the ability of Nrp1 to also bind the mature cytokine.
###end p 40
###begin title 41
Nrp1 activates LAP-TGF-beta1
###end title 41
###begin p 42
###xml 521 528 504 511 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 4A</bold>
###xml 521 528 504 511 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig"><bold>Fig. 4A</bold></xref>
###xml 662 671 639 648 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig">(Fig. 4B)</xref>
When T cells were activated with anti-CD3 mAb, proliferation and IL-2 production were suppressed by active TGF-beta1 (at </=2 pM; not shown). Suppression was also observed with LAP-TGF-beta1 but at much higher concentrations (50-200 pM), consistent with product information from the manufacturer and possibly because a fraction of this LAP-TGF-beta1 is activated in culture. The suppression exerted by LAP-TGF-beta1 was greatly increased when soluble Nrp1-Fc was added to cultures, revealing activation of LAP-TGF-beta1 (Fig. 4A). Similarly, LAP-TGF-beta1, in combination with Nrp1-Fc but not alone, suppressed the proliferation of TGF-beta-sensitive HT-2 cells (Fig. 4B). In both cases, proliferation was restored by an anti-TGF-beta mAb (1D11) that only binds the active form. Therefore, we conclude that Nrp1-Fc activates LAP-TGF-beta1.
###end p 42
###begin p 43
###xml 131 133 128 130 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B20" ref-type="bibr">20</xref>
###xml 133 135 130 132 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B21" ref-type="bibr">21</xref>
###xml 135 137 132 134 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B22" ref-type="bibr">22</xref>
###xml 274 283 268 277 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig">(Fig. 4C)</xref>
###xml 549 558 537 546 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig">(Fig. 4D)</xref>
Nrp1 has a sequence (RKFK) in its b2 domain, closely similar to a sequence of TSP-1 (KRFK or RFK) that activates latent TGF-beta1 [202122]. In the HT-2 assay, we found that the RKFK and KRFK peptides (but not control peptides) were equally effective at activating TGF-beta1 (Fig. 4C), and suppression was reversed by 1D11 mAb. The ability of Nrp1 to activate latent TGF-beta1 was further confirmed by our finding that coincubating LAP-TGF-beta1 with immobilized Nrp1-Fc in a cell-free system resulted in the exposure of an epitope recognized by1D11 (Fig. 4D). We hypothesize that this results in a change of conformation of LAP, where antigenic determinants of active TGF-beta1 are exposed, but it remains attached and can interact with 1D11 mAb.
###end p 43
###begin title 44
Nrp1-dependent activation of LAP-TGF-beta1 by breast cancer cells
###end title 44
###begin p 45
###xml 45 46 45 46 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 154 163 151 160 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 5, A</bold>
###xml 168 169 165 166 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 154 169 151 166 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig"><bold>Fig. 5, A</bold> and <bold>B</bold></xref>
###xml 251 268 248 265 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">(Fig. 5, C and D)</xref>
###xml 334 343 331 340 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">(Fig. 5E)</xref>
###xml 379 386 373 380 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">Fig. 5F</xref>
###xml 11 16 <span type="species:ncbi:9606">human</span>
###xml 389 394 <span type="species:ncbi:10090">Mouse</span>
MDA-MB-231 human breast cancer cells are Nrp1+ (data not shown). These cells captured LAP-TGF-beta1, which was markedly reduced by an anti-Nrp1 antibody (Fig. 5, A and B). The cells activated the latent cytokine as shown by increased p-Smad2 staining (Fig. 5, C and D), and this was almost completely blocked by an anti-Nrp1 antibody (Fig. 5E) or SD-208 (a TGF-betaRI inhibitor; Fig. 5F). Mouse Lewis lung carcinoma cells similarly captured LAP-TGF-beta1 in a Nrp1-dependent way (not shown).
###end p 45
###begin title 46
Conversion of conventional T cells into Tr cells in vitro
###end title 46
###begin p 47
###xml 16 17 16 17 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 21 22 21 22 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 26 27 26 27 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 294 295 291 292 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 299 300 296 297 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 456 457 453 454 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 461 462 458 459 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 694 703 685 694 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 6, A</bold>
###xml 708 709 699 700 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 694 709 685 700 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig"><bold>Fig. 6, A</bold> and <bold>B</bold></xref>
###xml 1036 1037 1021 1022 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1041 1042 1026 1027 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1172 1173 1157 1158 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1177 1178 1162 1163 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 1182 1183 1167 1168 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 1226 1235 1208 1217 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig">(Fig. 6B)</xref>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
Conventional CD4+CD25-Nrp1- naive (nonsuppressive), splenic T cells of C57BL/6 mice were incubated with Nrp1-Fc (or not), washed, and then incubated with LAP-TGF-beta1 (or not). As a control, Nrp1-Fc was replaced by Fc. These treated cells (or untreated cells) were washed and then added to CD4+CD25- T lymphocytes (the Te cells) in serum-free culture medium containing soluble CD3 mAb and irradiated APCs, and proliferation was measured. The untreated CD4+CD25- cells and single-treated cells (with Nrp1-Fc or LAP-TGF-beta1) were not suppressive or exerted only weak suppression, but the double-coated T cells (Nrp1-Fc/LAP-TGF-beta1-treated) strongly suppressed proliferation of the Te cells (Fig. 6, A and B). IL-2 secretion was also suppressed (not shown). When Nrp1-Fc was substituted by Fc, no suppression was observed. Importantly, the suppression exerted by Nrp1-Fc/LAP-TGF-beta1-treated cells was almost completely reversed by the 1D11 anti-TGF-beta mAb. Interestingly, the suppression exerted by naturally occurring, sorted CD4+Nrp1+ T cells, isolated from the spleen and tested ex vivo, was comparable (although slightly less) with the suppression exerted by CD4+CD25-Nrp1- T cells coated with Nrp1-Fc/LAP-TGF-beta1 (Fig. 6B).
###end p 47
###begin title 48
DISCUSSION
###end title 48
###begin p 49
###xml 620 622 608 610 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B23" ref-type="bibr">23</xref>
###xml 706 707 694 695 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">1</xref>
###xml 817 818 805 806 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">1</xref>
###xml 820 821 808 809 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">2</xref>
We demonstrate that Nrp1 is a high-affinity receptor for the active and latent forms of TGF-beta1. This is supported by several findings, including coprecipitation assays, cell-free ELISA-binding assays, competition with VEGF (a well-known Nrp1 ligand), use of blocking antibodies, flow cytometry data, and T cell functional assays. The binding affinities of Nrp1 for TGF-beta1 components (LAP, LAP-TGF-beta1, and TGF-beta1) were notably high. These high affinities likely depend on prominent avidity effects as a result of the homodimeric structure of Nrp1-Fc and the target ligands, as shown, for example, for VEGFR2 [23]. It appears that Nrp1 frequently exists as a dimer or oligomer on cell membranes [1], and therefore, similar high-affinity binding can probably occur in vivo. LAP binding to Nrp1, unlike VEGF [1, 2], is not enhanced by heparin but rather is blocked.
###end p 49
###begin p 50
###xml 60 61 60 61 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B5" ref-type="bibr">5</xref>
###xml 63 64 63 64 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B6" ref-type="bibr">6</xref>
###xml 163 164 163 164 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B5" ref-type="bibr">5</xref>
###xml 341 342 341 342 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B6" ref-type="bibr">6</xref>
###xml 449 452 449 452 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">165</sub>
###xml 618 620 618 620 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B24" ref-type="bibr">24</xref>
###xml 660 663 660 663 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">165</sub>
###xml 772 774 772 774 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B25" ref-type="bibr">25</xref>
###xml 814 817 814 817 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">165</sub>
###xml 872 874 872 874 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B26" ref-type="bibr">26</xref>
###xml 1014 1016 1014 1016 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B27" ref-type="bibr">27</xref>
###xml 1078 1082 1078 1082 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">RHRR</bold>
###xml 1210 1214 1210 1214 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">RHRR</bold>
Crystal structure studies of the b1 and b2 domains of Nrp1 [5, 6] provide possible explanations of how Nrp1 binds several seemingly unrelated ligands. Lee et al. [5] described a cleft with a negative charge within the b1 domain and postulated that positively charged C-terminal tails of VEGF and SEMA3 bind to this site. Vander Kooi et al. [6] reported similar findings and demonstrated that Tuftsin (TKPR), a peptide mimic of the C-terminal of VEGF165 (KPRR), binds to this cleft of the b1 domain. The terminal arginine residue of Tuftsin appears to be particularly important in this interaction. von Wronski et al. [24] showed that Tuftsin competes with VEGF165 for binding to Nrp1. Of note, a viral VEGF-like protein that binds Nrp1 has a C-terminal TRPPRRRR sequence [25]. In contrast, a splice variant of VEGF165 with a SLTRKD C-terminal sequence fails to bind Nrp1 [26]. In addition, other ligands or peptides that bind to Nrp1 are characterized by a basic structure and often two or more arginine residues [27]. As LAP has a highly basic, arginine-rich C-terminal motif (RHRR), we hypothesized that it binds to Nrp1 through this domain and tested some peptide interactions. A LAP C-terminal peptide (QSSRHRR) bound Nrp1, although with lower affinity than LAP, and blocked the binding of VEGF and LAP-TGF-beta1. Unlike VEGF, the binding of LAP was not blocked completely. Taken together, these observations are indicative of participation of the C-terminal LAP peptide in the binding LAP to Nrp1 but do not exclude the possibility that there are other binding sites, especially as LAP binding was not blocked completely.
###end p 50
###begin p 51
###xml 244 246 235 237 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B28" ref-type="bibr">28</xref>
###xml 248 250 239 241 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B29" ref-type="bibr">29</xref>
###xml 478 480 463 465 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B28" ref-type="bibr">28</xref>
###xml 482 484 467 469 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B29" ref-type="bibr">29</xref>
###xml 705 709 681 685 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">RKPK</bold>
###xml 1159 1161 1129 1131 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B27" ref-type="bibr">27</xref>
###xml 1192 1194 1162 1164 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">94</sup>
###xml 1194 1198 1164 1168 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">RKPK</bold>
###xml 1316 1318 1280 1282 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B30" ref-type="bibr">30</xref>
In the case of active TGF-beta1, there is no similar C-terminal sequence, and binding presumably occurs through other interactions that have not yet been characterized. However, crystal structure studies of TGF-beta3 and TGF-betaRII complexes [28, 29] show that TGF-beta3 has two arginine-containing, finger-like structures that interact with the RII receptor. In particular, the RII-binding site has an electronegative area, where D32 interacts with R94 of a TGF-beta3 finger [28, 29]. TGF-beta1 differs from TGF-beta3 by only one amino acid in that segment and is presumably capable of similar interactions. In preliminary studies, we found that a basic peptide encompassing R94 of TGF-beta1 (peptide VGRKPKV) interfered with the binding of mature TGF-beta and VEGF to Nrp1 (data not shown). In view of this, we speculate that the TGF-beta finger structure that binds to RII might also bind to the electronegative pocket of the b1 domain of Nrp1. It is interesting that this peptide did not have a C-terminal arginine residue, but in some cases, this may not be required as shown, for example, by the binding of cyclic arginine-containing peptides to Nrp1 [27]. Interestingly, the sequence 94RKPK of TGF-beta1 has been identified as a binding site to LAP, and remarkably, the RKPK peptide activated LAP-TGF-beta1 [30]. This peptide has obvious similarity with the basic peptides of Nrp1 (RKFK) and TSP-1 (KRFK), which also activate LAP-TGF-beta1, as discussed below.
###end p 51
###begin p 52
###xml 76 77 76 77 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 102 103 102 103 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 274 275 274 275 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 352 353 352 353 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 357 358 357 358 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 417 418 417 418 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 422 423 422 423 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 427 428 427 428 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 565 566 565 566 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 570 571 570 571 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 635 636 635 636 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 696 697 696 697 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 766 768 766 768 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B18" ref-type="bibr">18</xref>
###xml 793 794 793 794 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 926 927 926 927 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 931 932 931 932 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1035 1036 1023 1024 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1212 1213 1200 1201 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 783 788 <span type="species:ncbi:9606">human</span>
###xml 878 882 <span type="species:ncbi:10090">mice</span>
###xml 887 893 <span type="species:ncbi:9606">humans</span>
Flow cytometry analysis revealed that only 3-4% of splenic T cells were Nrp1+, and almost all were CD4+ cells, and they frequently coexpressed Tr markers (CD25, FoxP3, and LAP). However, these markers do not completely overlap, and there is obvious heterogenitiy in the Nrp1+ T cell population. By multicolor flow cytometry, we observed that 60% of CD4+CD25+ T cells coexpress Nrp1 and LAP. In addition, 10-12% of CD4+CD25+Nrp1- T cells also expressed LAP, suggesting that Nrp1 is not the only LAP receptor on the membrane of these T cells. Approximately 45% of CD4+CD25+ T cells coexpressed Nrp1 and FoxP3, and interestingly, the Nrp1+ cells expressed FoxP3 cells at a higher level than the Nrp1- T cells. This finding is similar to the report of Battaglia et al. [18], who studied human Nrp1+ Tr cells. Thus, Nrp1 expression appears to correlate with high FoxP3 expression in mice and humans. Approximately 40% of sorted CD4+Nrp1+ cells expressed LAP, but when these cells were incubated with soluble LAP, approximately95% became LAP+, revealing a high capacity to capture this component. The binding of LAP was blocked by an anti-Nrp1 antibody, showing this was a Nrp1-dependent interaction. In contrast, Nrp1- T cells only had a minimal ability to capture LAP, but this was considerably increased by precoating these cells with Nrp1-Fc. It is noteworthy that the blockade of other known receptors of LAP such as RGD-binding integrins and M6P/IGFII-R did not reduce the binding of LAP in our experiments (data not shown). Taken together, our results indicate that Nrp1 is the major LAP receptor of T cells, although it is not the only LAP receptor. The nature of other receptors has not been elucidated.
###end p 52
###begin p 53
###xml 172 174 172 174 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B12" ref-type="bibr">12</xref>
###xml 425 427 419 421 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B31" ref-type="bibr">31</xref>
###xml 923 925 908 910 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B20" ref-type="bibr">20</xref>
###xml 925 927 910 912 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B21" ref-type="bibr">21</xref>
###xml 927 929 912 914 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B22" ref-type="bibr">22</xref>
###xml 1007 1008 992 993 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B6" ref-type="bibr">6</xref>
###xml 1032 1034 1017 1019 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B32" ref-type="bibr">32</xref>
###xml 1354 1356 1336 1338 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B20" ref-type="bibr">20</xref>
###xml 1356 1358 1338 1340 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B21" ref-type="bibr">21</xref>
###xml 1358 1360 1340 1342 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B22" ref-type="bibr">22</xref>
###xml 1613 1615 1592 1594 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B32" ref-type="bibr">32</xref>
###xml 1590 1593 <span type="species:ncbi:10116">rat</span>
###xml 1595 1600 <span type="species:ncbi:10090">mouse</span>
###xml 1606 1611 <span type="species:ncbi:9606">human</span>
No definite role has yet been ascribed to Nrp1 in Tr cell-suppressive activity. Indeed, antibodies against Nrp1 did not alter the suppressive activity of natural Tr cells [12]. However, we hypothesized that Nrp1 might play a role by capturing LAP-TGF-beta1 and contributing to its activation on the cell membrane. There is a precedent for this, as other molecules can activate latent TGF-beta1 on the membrane of some cells [31]. First, we found that the coincubation of soluble Nrp1-Fc and LAP-TGF-beta1 resulted in activation of the cytokine, as measured by suppression of HT-2 cells or normal T cells. Although the mechanism of TGF-beta1 activation remains to be elucidated, it is striking that Nrp1 possesses a short basic sequence (RKFK) in its b2 domain, closely similar to a sequence of TSP-1 (KRFK or RFK) that binds LAP in its N-terminal portion and activates latent TGF-beta1 by inducing a conformational change [202122]. Importantly, the RKFK sequence of Nrp1 has been linked to heparin binding [6] and cell aggregation [32] and is evidently exposed for molecular interactions. We compared the RKFK and KRFK peptides and found that they are equally effective at activating latent TGF-beta1. Although further studies are required, this suggests that the RKFK sequence of Nrp1 represents another binding site for LAP and by analogy, with TSP-1 [202122], provides an important clue as to how it might activate LAP-TGF-beta1. Indeed, our binding studies suggest more than one site for interaction of LAP with Nrp1. Interestingly, the RKFK sequence is present in Nrp1 and Nrp2 of the rat, mouse, and human [32].
###end p 53
###begin p 54
###xml 53 54 53 54 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">1</xref>
###xml 230 231 227 228 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 180 185 <span type="species:ncbi:9606">human</span>
Most malignant tumor cells express Nrp1 and/or Nrp2 [1], and it was of interest to see whether this influences LAP-TGF-beta1 capture. We investigated this question with MDA-MB-231 human breast cancer cells, which are strongly Nrp1+. These cells captured LAP-TGF-beta1, and LAP staining was greatly reduced by an anti-Nrp1 antibody, although some weak staining persisted, perhaps because of another receptor(s). Importantly, LAP-TGF-beta1 was activated, as demonstrated by increased nuclear p-Smad2 expression, and this was almost completely blocked by an anti-Nrp1 antibody. The generation of p-Smad2 is strong evidence of the induction TGF-beta1 signaling, and this is a Nrp1-dependent process. As expected, a TGF-betaRI (ALK5) inhibitor, SD-208, also blocked signaling in this pathway.
###end p 54
###begin p 55
###xml 88 89 88 89 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 93 94 93 94 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 98 99 98 99 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 278 279 275 276 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 287 288 284 285 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 644 645 638 639 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 649 650 643 644 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 654 655 648 649 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 1172 1173 1151 1152 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1243 1244 1219 1220 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1478 1480 1448 1450 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B31" ref-type="bibr">31</xref>
###xml 1577 1579 1544 1546 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B13" ref-type="bibr">13</xref>
###xml 1826 1827 1793 1794 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B3" ref-type="bibr">3</xref>
###xml 1862 1864 1829 1831 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B33" ref-type="bibr">33</xref>
###xml 1909 1911 1876 1878 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B33" ref-type="bibr">33</xref>
###xml 1968 1970 1932 1934 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B34" ref-type="bibr">34</xref>
To demonstrate an effect on T cell activity, we coated conventional (nonsuppressive) CD4+CD25-Nrp1- cells with Nrp1-Fc and LAP-TGF-beta1 and tested their activity in a Tr cell assay (inhibition of CD3-mediated T cell proliferation). Of note, Nrp1-Fc binds to the membrane of CD4+ and CD8+ T cells, as well as tumor cell lines (data not shown). The receptors responsible for this interaction have not been characterized. However, as Nrp1 binds to several molecules commonly expressed on cell membranes (e.g., VEGF receptors, cMET, beta1 integrin, galectin-1), it seems likely that several receptors are capturing soluble Nrp1. Single-treated CD4+CD25-Nrp1- cells (with Nrp1-Fc or LAP-TGF-beta1) exerted minimal or no suppression, and double-coated T cells were strongly suppressive. Furthermore, this suppression was almost completely reversed by the 1D11 anti-TGF-beta mAb, indicating that activated TGF-beta1 was involved. We conclude that Nrp1 captured and activated TGF-beta1 and through this mechanism, converted Te cells into Tr cells. As TGF-beta1 is secreted primarily in the LAP-bound, latent form, which is present in plasma and tissues, it seems likely that Nrp1+ T cells will acquire LAP-TGF-beta1 in vivo, although not all were LAP+. We speculate that Nrp1 allows T cells to capture and maintain TGF-beta1 in an active form on their membrane and exert Tr-like suppression. This could be because these T cells are induced by TGF-beta1 to differentiate into Tr cells [31] or because membrane-bound TGF-beta1 directly exerts suppression, as suggested by some authors [13]. Under physiological conditions, the association of Nrp1 with the PDZ protein GIPC might be relevant. Nrp1 interacts with GIPC through a short C-terminal (cytoplasmic) sequence (SEA), and this segment is required for Nrp1-mediated angiogenesis [3]. GIPC is a PDZ scaffold protein [33] and can link G-protein signaling pathways [33]. It is also intriguing that Nrp1 and the TGF-betaRIII [34] have a GIPC-binding domain, and it is plausible that they interact through this cytoplasmic protein. However, in our experiments, Nrp1-Fc does not have the GIPC-binding domain, demonstrating that GIPC is not required for the enhancement of LAP-TGF-beta1-suppressive activity, presumably as signaling occurs through the classical TGF-betaRs (RI, RII, RIII).
###end p 55
###begin p 56
###xml 49 50 49 50 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 54 55 54 55 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 204 206 204 206 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B35" ref-type="bibr">35</xref>
###xml 276 277 276 277 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 409 410 409 410 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 437 440 437 440 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">165</sub>
###xml 496 497 496 497 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 517 518 517 518 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
In our Tr cell assays, we artificially coated CD4+CD25- T cells with Nrp1-Fc, and the question arises whether these cells can express Nrp1 in vivo. With respect to this question, Bourbie-Vaudaine et al. [35] showed that Nrp1 is transferred from DCs (which express Nrp1) to CD4+ T cells during T cell/DC interactions by a process denoted trogocytosis. Interestingly, Nrp1 was not rapidly internalized, and Nrp1+ T cells could capture VEGF165 on their membrane. In this case, >60% of responding CD4+ T cells became Nrp1+, and although we have not studied this question, we hypothesize that when TGF-beta1 is abundant, this could duplicate the conditions of our Tr assay.
###end p 56
###begin p 57
###xml 341 342 332 333 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">1</xref>
###xml 344 346 335 337 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B31" ref-type="bibr">31</xref>
###xml 514 515 502 503 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">1</xref>
###xml 517 518 505 506 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">2</xref>
###xml 520 521 508 509 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B7" ref-type="bibr">7</xref>
###xml 521 522 509 510 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B8" ref-type="bibr">8</xref>
###xml 522 523 510 511 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B9" ref-type="bibr">9</xref>
###xml 523 525 511 513 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B10" ref-type="bibr">10</xref>
###xml 832 834 820 822 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B36" ref-type="bibr">36</xref>
In conclusion, we present evidence that Nrp1 is a receptor for the latent and active forms of TGF-beta1, activates the latent form, and promotes Tr activity. Nrp1-dependent TGF-beta1 activation also occurred on the membrane of breast cancer cells, and this is of great interest, as Nrp1 and TGF-beta1 have been linked to cancer progression [1, 31]. Also of notable relevance to cancer, Nrp1 acts as a coreceptor in VEGF/VEGFR and HGF/cMet interactions and also binds fibroblast growth factor 2 and beta1 integrin [1, 2, 78910]. This astonishing variety of interactions suggests that Nrp1 has a general function of capturing growth factors on the membrane of normal or tumor cells and enhancing signaling through several pathways. Perhaps this occurs in some cases through the incorporation of Nrp1 into multicomponent signalosomes [36] involved in these pathways, with the participation of scaffold proteins such as GIPC. TGF-beta1 is produced primarily in latent form (unlike other cytokines), and in this case, Nrp1 has the additional capacity of activating the latent cytokine. Our studies point to novel interactions between Nrp1 and TGF-beta1, which are potentially relevant to several biological processes such as angiogenesis, immune regulation, and tumor biology.
###end p 57
###begin p 58
This study was supported by Ontario Institute for Cancer Research of the Province of Ontario (Canada), the Juvenile Diabetes Foundation International, the Canadian Diabetes Association, the Krembil Foundation (Toronto, Canada), and the Li Ka Shing Knowledge Institute and Keenan Research Centre of St. Michael's Hospital (Toronto, Canada).
###end p 58
###begin article-title 59
Neuropilins in physiological and pathological angiogenesis
###end article-title 59
###begin article-title 60
Vascular endothelial growth factor (VEGF) signaling in tumor progression
###end article-title 60
###begin article-title 61
Neuropilin-1 modulates p53/caspases axis to promote endothelial cell survival
###end article-title 61
###begin article-title 62
Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165
###end article-title 62
###begin article-title 63
###xml 25 30 <span type="species:ncbi:9606">human</span>
Crystal structure of the human neuropilin-1 b1 domain
###end article-title 63
###begin article-title 64
Structural basis for ligand and heparin binding to neuropilin B domains
###end article-title 64
###begin article-title 65
Neuropilin-1 interacts with integrin beta1 and modulates pancreatic cancer cell growth, survival and invasion
###end article-title 65
###begin article-title 66
Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1
###end article-title 66
###begin article-title 67
Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity
###end article-title 67
###begin article-title 68
Interactions of multiple heparin binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2
###end article-title 68
###begin article-title 69
A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response
###end article-title 69
###begin article-title 70
Neuropilin-1: a surface marker of regulatory T cells
###end article-title 70
###begin article-title 71
TGF-beta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling
###end article-title 71
###begin article-title 72
###xml 85 89 <span type="species:ncbi:10090">mice</span>
Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice
###end article-title 72
###begin article-title 73
6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-beta1
###end article-title 73
###begin article-title 74
Protective regulatory T cell generation in autoimmune diabetes by DNA covaccination with islet antigens and a selective CTLA-4 ligand
###end article-title 74
###begin article-title 75
CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness
###end article-title 75
###begin article-title 76
###xml 69 74 <span type="species:ncbi:9606">human</span>
Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer
###end article-title 76
###begin article-title 77
###xml 49 55 <span type="species:ncbi:10090">murine</span>
Neuropilin 1 and CD25 co-regulation during early murine thymic differentiation
###end article-title 77
###begin article-title 78
Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1
###end article-title 78
###begin article-title 79
Thrombospondin-1 is a major activator of TGF-beta1 in vivo
###end article-title 79
###begin article-title 80
The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta
###end article-title 80
###begin article-title 81
Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor
###end article-title 81
###begin article-title 82
Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon 8 of vascular endothelial growth factor
###end article-title 82
###begin article-title 83
###xml 60 69 <span type="species:ncbi:10258">orf virus</span>
Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1
###end article-title 83
###begin article-title 84
VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma
###end article-title 84
###begin article-title 85
Targeting neuropilin 1 as an antitumor strategy in lung cancer
###end article-title 85
###begin article-title 86
###xml 25 30 <span type="species:ncbi:9606">human</span>
Crystal structure of the human TbetaR2 ectodomain-TGF-beta3 complex
###end article-title 86
###begin article-title 87
Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding
###end article-title 87
###begin article-title 88
Molecular interactions that confer latency to transforming growth factor-beta
###end article-title 88
###begin article-title 89
Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations
###end article-title 89
###begin article-title 90
Determination of cell adhesion sites of neuropilin-1
###end article-title 90
###begin article-title 91
RGS proteins have a signaling complex: interactions between RGS proteins and GPCRs, effectors, and auxiliary proteins
###end article-title 91
###begin article-title 92
A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC
###end article-title 92
###begin article-title 93
Dendritic cells can turn CD4+ T lymphocytes into vascular endothelial growth factor-carrying cells by intercellular neuropilin-1 transfer
###end article-title 93
###begin article-title 94
Compartmentalization of growth factor receptor signaling
###end article-title 94
###begin p 95
Nrp1 binds TGF-beta1 components. (A) LAP-TGF-beta1, LAP (beta1), TGF-beta1, and VEGF bound to Nrp1-Fc (but not control Fc) and were retained on protein G-sepharose beads. Bound proteins were recovered and immunoblots performed with specific antibodies. Molecular weight markers are indicated. (B) To demonstrate binding by ELISA, Nrp1-Fc-coated plates were incubated with increasing concentrations of the ligands. LAP (alone but not in the presence of 2 mug/ml heparin) and LAP-TGF-beta1 bound at high affinity to Nrp1-Fc (see text). Several control proteins, including IFN-gamma and IL-2, did not bind (not shown). (C) Active TGF-beta1 bound to immobilized Nrp1-Fc. (D) Soluble Nrp1-Fc bound to plate-bound LAP, and this was inhibited by an anti-LAP antibody. The data in A-D are representative of three or more independent experiments.
###end p 95
###begin p 96
Mature TGF-beta1 and LAP compete with VEGF for binding to Nrp1-Fc. (A) TGF-beta1 and free LAP but not BSA-reduced binding of VEGF (2 nM) to the plate coated with 1 nM Nrp1-Fc. (B) Premixing LAP-TGF-beta with VEGF (1 nM each) decreased the retention of VEGF by the Nrp1-Fc-coated plate. Under the same conditions, IFN-gamma did not affect the VEGF retention. (C) Immobilized LAP C-terminal peptide, QSSRHRR, but not control peptide, bound soluble Nrp1-Fc. (D) Soluble QSSRHRR peptide reduced binding of LAP, LAP-TGF-beta1, and VEGF to immobilized Nrp1-Fc (1 nM). The data in A-D are representative of two or three independent experiments.
###end p 96
###begin p 97
###xml 335 336 329 330 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 339 340 333 334 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 529 530 523 524 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 534 535 528 529 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 561 562 555 556 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 567 568 561 562 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 612 613 606 607 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 681 682 675 676 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 686 687 680 681 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 705 708 697 700 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">sem</sc>
###xml 796 797 788 789 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 846 847 838 839 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 927 928 919 920 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 980 981 972 973 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 985 986 977 978 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 97 102 <span type="species:ncbi:10090">mouse</span>
###xml 718 722 <span type="species:ncbi:10090">mice</span>
###xml 765 769 <span type="species:ncbi:10090">mice</span>
Coexpression of Nrp1 and TGF-beta components analyzed by flow cytometry. (A) Approximately 3% of mouse splenic T cells coexpressed LAP and Nrp1 (percent-positive cells are indicated on the histograms). (B) Splenic T cells were incubated with Nrp1-Fc, washed, and incubated with LAP-TGF-beta1. This approximately tripled the number Nrp1+LAP+ cells. (C and D) Splenic T cells were stained in four colors with antibodies against CD4, CD25, Nrp1, and LAP (C) or forkhead box P3 (FoxP3; D). The two-dimensional plots were gated on CD4+CD25+ cells. The number of Nrp1-FoxP3+ T cells is circled in D and shows that Nrp1+ cells generally express more FoxP3. (E) Tr-marker expression in CD4+Nrp1+ cells (percent+/-sem) in CD-1 mice. Similar results were obtained in C57BL/6 mice (not shown). (F) When Nrp1+ cells were incubated with LAP, the number of LAP+ cells increased from 40% to 95%, and this was blocked by an anti-Nrp1 mAb. Nrp1- T cells only minimally captured LAP. (G) Sorted CD4+Nrp1- T cells incubated with Nrp1-Fc and LAP-TGF-beta1 capture LAP-TGF-beta1 (LAP staining shown), and this was blocked by an anti-Nrp1 mAb. Silver peak, Isotype control; gray line/cross hatched peak, anti-LAP staining; solid black line, incubation with Nrp1-Fc and LAP-TGF-beta1; dotted black line, incubation with Nrp1-Fc, then anti-Nrp1 mAb, and then LAP-TGF-beta1. (H) T cells were incubated (or not) with Nrp1-Fc and then with active TGF-beta1. Silver line, Isotype control; gray line/cross hatched peak, TGF-beta1 staining; solid black line, T cell incubated with TGF-beta1; dotted black line, T cells incubated with Nrp1-Fc and then TGF-beta1. (A-H) The results are representative of two or more independent experiments. Cells were washed between treatments with Nrp1-Fc and TGF-beta1 components.
###end p 97
###begin p 98
Nrp1-Fc and Nrp1 peptides activate LAP-TGF-beta1. (A) Soluble Nrp1-Fc (0.4 nM) induced inhibition by LAP-TGF-beta1 (0.2 nM) of the proliferation of T cells (CD3 mAb-stimulated), and this was abrogated by the 1D11 anti-TGF-beta antibody (50 mug/ml) reactive only to active TGF-beta. (B) LAP-TGF-beta1 (2 nM) gained the ability to suppress the proliferation of HT-2 cells in the presence of Nrp1-Fc (5 nM), and this was abrogated by 1D11 mAb. In some wells, LAP-TGF-beta1 and 1D11 were added without Nrp1-Fc (as a negative control), and as expected, this did not inhibit proliferation (not shown). (C) Nrp1 peptide RKFK and thrombospondin-1 (TSP-1) peptide KRFK were equally effective at activating LAP-TGF-beta (2 nM), as determined in the HT-2 proliferation assay, and this was blocked by the 1D11 mAb. (D) Binding of LAP-TGF-beta1 to immobilized Nrp1-Fc exposed a TGF-beta1 epitope recognized by 1D11 mAb.
###end p 98
###begin p 99
###xml 21 22 21 22 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 11 16 <span type="species:ncbi:9606">human</span>
MDA-MB-231 human Nrp1+ breast cancer cells bind and activate latent TGF-beta1. (A) Incubation of the cells with LAP-TGF-beta1 and fluorescent LAP staining showing retention of LAP. (B) Cells treated with anti-Nrp1 mAb-blocking antibody and LAP-TGF-beta1 and stained for LAP. (C) p-Smad2 fluorescent staining of untreated cultured cells. (D) p-Smad2 staining of cells incubated with LAP-TGF-beta1. (E) p-Smad2 staining of cells incubated with anti-Nrp1 antibody and LAP-TGF-beta1. (F) p-Smad2 staining of cells incubated with SD-208 and LAP-TGF-beta1. The results of A-F are representative of three separate experiments.
###end p 99
###begin p 100
###xml 63 64 63 64 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 133 134 133 134 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 138 139 138 139 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 330 331 330 331 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 335 336 335 336 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 608 609 602 603 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 766 767 757 758 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 771 772 762 763 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</sup>
###xml 934 935 918 919 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 939 940 923 924 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Acquisition of Tr-like suppressive activity by conventional CD4+ T cells. We tested suppression in a conventional Tr assay, where CD4+CD25- T cells (the Te cells) are activated by soluble CD3 mAb. Putative Ts cells were added to Te cells, and decreased proliferation is used as an indicator of suppression. (A) Nrp1-Fc-treated CD4+CD25- T cells and Fc-treated cells did not suppress proliferation (data represent 1:1 Ts:Te ratio). LAP-TGF-beta1-treated T cells were weakly suppressive. However, Nrp1-Fc/LAP-TGF-beta1 double-treated T cells were strongly suppressive (1:1 Ts:Te ratio; see B for other ratios; P<0.0001 vs. all single-treated T cells). The suppressive effect was not seen when Nrp1-Fc was replaced by Fc. (B) Nrp1-Fc and LAP-TGF-beta1 double-coated CD4+CD25- T cell-mediated suppression was TGF-beta-dependent. The suppression was almost completely reversed by 1D11 anti-TGF-beta mAb (50 mug/ml). Naturally occurring CD4+Nrp1+ T cells (sorted ex vivo) produced a comparable degree of suppression. The data are representative of three independent experiments.
###end p 100

